Disclosed is the use of a composition comprising nanoparticles that comprise rapamycin or a derivative thereof and a carrier protein in the manufacture of a medicament for treating cancer in an individual, wherein the composition is used in combination with another chemotherapeutic selected from the group consisting of an antimetabolite agent, a Platinum-based agent, an alkylating agent, a tyrosine kinase inhibitor, an anthracycline antibiotic, a vinca alkaloid, a proteasome inhibitor, a topoisomerase inhibitor, an AKT kinase inhibitor, a therapeutic antibody, a p110&alpha；-specific inhibitor, an agent affecting a signalling pathway involving TORC1, an agent affecting a signalling pathway involving TORC2, an inhibitor of the PI3K/Akt pathway, a colchicine or thiocolchicine dimer or derivative thereof, and an interferon.
